Table 1.
Demographic data for newly diagnosed diabetic patients according to antidiabetic monotherapy
| Hypoglycemic | Metformin | Glitazone | Sulfonylurea | Meglitinide | Acarbose | Insulin | Total |
|---|---|---|---|---|---|---|---|
| N (%) | 2,223 | 53 | 3,965 | 128 | 150 | 806 | 7,325 |
| Age (year) | |||||||
| Median (IQR)** | 60.6 (19.5) | 61.0 (21.2) | 62.4 (19.9) | 67.2 (23.4) | 63.5 (22.6) | 70.6 (22.5) | 62.6 (20.4) |
| 30–39 | 128 (5.8) | 3 (5.7) | 177 (4.5) | 5 (3.9) | 12 (8.0) | 57 (7.1) | 382 (5.2) |
| 40–49 | 359 (16.1) | 7 (13.2) | 667 (16.8) | 12 (9.4) | 17 (11.3) | 75 (9.3) | 1,137 (15.5) |
| 50–59 | 598 (26.9) | 15 (28.3) | 931 (23.5) | 34 (26.6) | 36 (24.0) | 111 (13.8) | 1,725 (23.5) |
| 60–69 | 541 (24.3) | 10 (18.9) | 1,018 (25.7) | 21 (16.4) | 37 (24.7) | 143 (17.7) | 1,770 (24.2) |
| 70–79 | 469 (21.1) | 16 (30.2) | 864 (21.8) | 31 (24.2) | 37 (24.7) | 234 (29.0) | 1,651 (22.5) |
| ≥80 | 128 (5.8) | 2 (3.8) | 308 (7.8) | 25 (19.5) | 11 (7.3) | 186 (23.1) | 660 (9.0) |
| Sex* | |||||||
| Woman | 1,028 (46.2) | 21 (39.6) | 1,730 (43.6) | 53 (41.4) | 82 (54.7) | 349 (43.3) | 3,263 (44.5) |
| Man | 1,195 (53.8) | 32 (60.4) | 2,235 (56.4) | 75 (58.6) | 68 (45.3) | 457 (56.7) | 4,062 (55.5) |
| CCI | |||||||
| Median (IQR)** | 1.0 (2.0) | 1.0 (2.0) | 1.0 (2.0) | 1.0 (2.0) | 1.0 (2.0) | 2.0 (3.0) | 1.0 (2.0) |
| 0 | 1,038 (46.7) | 24 (45.3) | 1,600 (40.4) | 57 (44.5) | 61 (40.7) | 123 (15.3) | 2,903 (39.6) |
| 1 | 609 (27.4) | 11 (20.8) | 1,002 (25.3) | 27 (21.1) | 41 (27.3) | 161 (20.0) | 1,851 (25.3) |
| 2 | 297 (13.4) | 10 (18.9) | 578 (14.6) | 16 (12.5) | 22 (14.7) | 138 (17.1) | 1,061 (14.5) |
| 3 | 134 (6.0) | 3 (5.7) | 336 (8.5) | 7 (5.5) | 14 (9.3) | 131 (16.3) | 625 (8.5) |
| 4 | 70 (3.1) | 1 (1.9) | 219 (5.5) | 11 (8.6) | 5 (3.3) | 89 (11.0) | 395 (5.4) |
| 5 | 41 (1.8) | 3 (5.7) | 105 (2.6) | 3 (2.3) | 5 (3.3) | 68 (8.4) | 225 (3.1) |
| 6 | 20 (0.9) | 1 (1.9) | 69 (1.7) | 5 (3.9) | 1 (0.7) | 38 (4.7) | 131 (1.8) |
| ≥7 | 14 (0.6) | 0 (0.0) | 56 (1.4) | 2 (1.6) | 1 (0.7) | 58 (7.2) | 134 (1.8) |
| Smoking-related diagnoses** | 295 (13.3) | 8 (15.1) | 656 (16.5) | 18 (14.1) | 15 (10.0) | 213 (26.4) | 1,205 (16.5) |
| Alcohol use disorder** | 48 (2.2) | 1 (1.9) | 120 (3.0) | 5 (3.9) | 4 (2.7) | 54 (6.7) | 232 (3.2) |
| Morbid obesity** | 70 (3.1) | 2 (3.8) | 33 (0.8) | 1 (0.8) | 6 (4.0) | 3 (0.4) | 115 (1.6) |
| Pancreatitis** | 11 (0.5) | 0 (0.0) | 41 (1.0) | 3 (2.3) | 3 (2.0) | 44 (5.5) | 102 (1.4) |
| Hypertension | 1,447 (65.1) | 39 (73.6) | 2,544 (64.2) | 83 (64.8) | 93 (62.0) | 480 (59.6) | 4,686 (64.0) |
| Hyperlipidemia** | 1,133 (51.0) | 27 (50.9) | 1,756 (44.3) | 55 (43.0) | 67 (44.7) | 161 (20.0) | 3,199 (43.7) |
| Monthly income in NTD** | |||||||
| 1–19,999 | 1,450 (65.2) | 29 (54.7) | 2,853 (72.0) | 99 (77.3) | 103 (68.7) | 606 (75.2) | 5,140 (70.2) |
| 20,000–39,999 | 349 (15.7) | 11 (20.8) | 459 (11.6) | 8 (6.2) | 19 (12.7) | 48 (6.0) | 894 (12.2) |
| ≥40,000 | 205 (9.2) | 8 (15.1) | 239 (6.0) | 5 (3.9) | 8 (5.3) | 29 (3.6) | 494 (6.7) |
| Missing data | 219 (9.9) | 5 (9.4) | 414 (10.4) | 16 (12.5) | 20 (13.3) | 123 (15.3) | 797 (10.9) |
| Urbanization level** | |||||||
| Most urbanized | 664 (29.9) | 17 (32.1) | 996 (25.1) | 32 (25.0) | 30 (20.0) | 192 (23.8) | 1,931 (26.4) |
| More | 652 (29.3) | 16 (30.2) | 1,084 (27.3) | 29 (22.7) | 45 (30.0) | 200 (24.8) | 2,026 (27.7) |
| Moderate | 368 (16.6) | 9 (17.0) | 631 (15.9) | 20 (15.6) | 22 (14.7) | 148 (18.4) | 1,198 (16.4) |
| Less | 289 (13.0) | 6 (11.3) | 685 (17.3) | 20 (15.6) | 30 (20.0) | 133 (16.5) | 1,163 (15.9) |
| Least | 250 (11.2) | 5 (9.4) | 569 (14.4) | 27 (21.1) | 23 (15.3) | 133 (16.5) | 1,007 (13.7) |
| Duration of follow-up (years) | |||||||
| Median (IQR)** | 2.4 (2.9) | 2.8 (2.8) | 2.8 (3.9) | 2.8 (3.5) | 2.1 (2.7) | 1.6 (3.7) | 2.5 (3.6) |
| ≤3 | 1,345 (60.5) | 28 (52.8) | 2,104 (53.1) | 92 (71.9) | 92 (61.3) | 535 (66.4) | 4,196 (57.3) |
| >3 to ≤5 | 473 (21.3) | 19 (35.8) | 829 (20.9) | 23 (18.0) | 40 (26.7) | 112 (13.9) | 1,496 (20.4) |
| >5 to ≤7 | 198 (8.9) | 6 (11.3) | 482 (12.2) | 11 (8.6) | 18 (12.0) | 60 (7.4) | 775 (10.6) |
| >7 to ≤9 | 154 (6.9) | 0 (0.0) | 373 (9.4) | 2 (1.6) | 0 (0.0) | 53 (6.6) | 582 (7.9) |
| >9 | 53 (2.4) | 0 (0.0) | 177 (4.5) | 0 (0.0) | 0 (0.0) | 46 (5.7) | 276 (3.8) |
Notes:
*
P<0.05,
**
P<0.001.
Abbreviations: IQR, interquartile range; CCI, Charlson comorbidity index; NTD, new Taiwan dollar.